From Chatbots to Co-Pilots — Why Pharma Needs Agentic AI

Filter by:

You might also like:

Episode 8: Launching Lumara

Episode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignment across Access, HEOR, Medical, and Field.

Episode 7: Lessons from Elsewhere –– What Other TAs Are Doing Better

Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch.

Episode 6: The Unknown Unknowns

Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening, field feedback loops, KOL digital patterns, and payer advisory monitoring translate into real decisions.

Episode 5: Scaling the Access Wall

Episode 5 examines how real-world evidence (RWE) is now the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations.

Episode 4: Message Battles

In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible payer narrative — one that can cut through entrenched positioning and resonate with pharmacy and medical directors.

Episode 3: Patient Support Showdown

Episode 3 zeroes in on the first-fill moment and early adherence—where HUB design, copay policy, and specialty-pharmacy handoffs can make or break momentum. We unpack the essentials of high-performing programs (benefits investigation, real-time PA tracking, FRM support, nurse case management, and digital enrollment) and spotlight where patients and offices most often stall.

Lumara Series Episode 2: The Coverage Chessboard

Episode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers.

Lumara Series Episode 1: Meet Lumara

In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market.

Trailer: The Lumara Series

Series Overview: The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially...

What Airbnb’s AI-First Pivot Means for Specialty Pharma

The seamless, AI-powered experiences consumers encounter in travel, retail, and entertainment shape their expectations of what healthcare support should feel like.

How AI Voice Technology Reshaped Publishing—and What It Means for Pharma.

Turning Up the Volume: How AI Voice Technology Reshaped Publishing—and What It Means for Other Industries Artificial intelligence is now...

Breaking Down Barriers: Why Pharma Must Simplify Eligibility Criteria

Patients facing cancer, autoimmune disease, or rare disorders don’t have time to spare—but too often, the very first step in their...

From Chatbots to Co-Pilots — Why Pharma Needs Agentic AI

What if your most consistent team member never got tired, forgot nothing, escalated wisely, and worked 24/7 without complaint?

Greg Johnsen
Sep 5, 2025
3 min read

While Pharma continues to experiment with chatbots, other industries have already moved on—deploying agentic AI: intelligent systems that don’t just respond, but act, learn, and orchestrate. These AI agents are becoming full-service teammates: resolving issues, guiding journeys, and improving outcomes autonomously.

Ask not what AI can answer—ask what job it can do.

What Is Agentic AI, and Why Does It Matter?

Agentic AI refers to systems that can:

Perceive context (through data, inputs, behavior)
Decide what needs to happen
Act to complete tasks or solve problems
Learn from experience

In contrast to traditional chatbots or automation, agentic AI is stateful, adaptive, and goal-oriented. It’s less like a help desk and more like a digital colleague.

And while Pharma often frames AI as “a smarter way to answer questions,” here’s how other industries are already deploying agentic systems today:

Salesforce: 66% of website inquiries are now resolved by autonomous AI agents, reducing handoffs and accelerating support
Walmart: AI agents like Sparky coordinate supply chain operations and optimize consumer touchpoints across the entire business
Adobe: Specialized agents manage content creation, campaign performance, and customer journey optimization without human prompting

These are not AI “tools.” These are AI workers—embedded in workflows and held accountable for results.

What This Means for Specialty Pharma

Today’s PSPs, hubs, and field workflows are dominated by:

Static scripts
Linear logic trees
Phone follow-ups
Human coordination gaps

The opportunity isn’t just to “automate tasks.” It’s to deploy intelligent agents that get the job done.

Current State	Agentic Future
Reactive chatbot that answers questions	Proactive support agent that flags and fixes delays
Form-heavy onboarding portal	Conversational AI navigator that adapts to patient responses
Manual escalation of benefits issues	AI agent that monitors claim status and intervenes
Static field team content	AI copilot that prepares briefings based on CRM and past HCP interactions

The best AI in Pharma won’t just sit in a chat window.

It’ll be in the background—resolving things, reminding people, rerouting workflows, and lifting the administrative burden from humans.

Genflare’s POV: It’s Time to Rethink the AI Mandate

Right now, many commercial teams in Pharma are investing in AI pilots. But too often, they’re limiting the field of opportunity by focusing on just a couple of standard questions:

“What can this AI answer?” Or “What can this AI generate?”

Consider expanding the field, and asking questions that can lead to a force-multiplier::

What job could this AI do in our PSP?
What problem could it solve for our patients?
What work could it take off the plate of our reps or case managers?
What delays could it prevent before they cost us adherence?

And most important:

What if your most consistent team member never got tired, forgot nothing, escalated wisely, and worked 24/7 without complaint?

That’s what agentic AI can offer—not in 10 years, but now.

The Takeaway for Pharma Leaders

Pharma isn’t behind on AI because of technology.

It’s behind because of imagination—a failure to see that the job of AI isn’t just to explain. It’s to execute and scale the business.

Agentic AI is already being used across sectors to handle customer journeys, triage errors, and drive outcomes.

Who in Pharma will be bold enough to stop asking what AI can answer, or generate—and start deploying it to do the work that matters?

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.